Conditions: Cholangiocarcinoma; Brain Tumor; Urothelial Cancer; Other Tumor Types With FGFR2 Gene Fusions; Activating Mutations; FGFR2 Amplification
Intervention: Drug: TAS-120
Sponsor: Taiho Oncology, Inc.
**RECRUITING NOW**
Intervention: Drug: TAS-120
Sponsor: Taiho Oncology, Inc.
**RECRUITING NOW**
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
